Katacalcin (PDN 21)
(Synonyms: 抗钙素; PDN 21) 目录号 : GC33793
Katacalcin (PDN 21) (PDN 21) 是一种有效的血浆降钙肽。
Cas No.:85916-47-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Katacalcin is a second potent plasma calcium-lowering peptide.
Katacalcin is a potent plasma calcium lowering peptide. Katacalcin belongs to the calcitonin family, that causes a rapid but short-lived drop in the level of calcium and phosphate in blood by promoting the incorporation of these ions in the bones[1]. Katacalcin (KC) belongs to a small family of polypeptides that are encoded by the calc-1 gene and also include calcitonin (CT) and procalcitonin NH2-terminal cleavage peptide (N-ProCT). Katacalcin pretreatment leads to a concentration-dependent decrease at concentrations between 1 amol/liter and 10 fmol/liter and is a more potent inhibitor of fMLP-induced chemotaxis than CT or procalcitonin (PCT). Katacalcin deactivates CD14+ peripheral blood mononuclear cell (PBMC) chemotaxis not only toward N-formyl-Met-Leu-Phe (fMLP) but also toward other attractants of the chemokine family (heterologous deactivation) as well as toward PCT and CT. Pretreatment of CD14+ PBMCs with Katacalcin also deactivates subsequent chemotaxis toward Katacalcin itself. Katacalcin elicites concentration-dependent migration of CD14+ PBMC at concentrations from the atomolar to the micromolar range and deactivates attractant-induced chemotaxis. Katacalcin regulates human CD14+ PBMC migration via signaling events involving protein kinase A-dependent cAMP pathways[2].
[1]. Hillyard CJ, et al. Katacalcin: a new plasma calcium-lowering hormone. Lancet. 1983 Apr 16;1(8329):846-8. [2]. Kaneider NC, et al. Involvement of cyclic adenosine monophosphate-dependent protein kinase A and pertussis toxin-sensitive G proteins in the migratory response of human CD14+ mononuclear cells tokatacalcin. J Bone Miner Res. 2002 Oct;17(10):1872-82.
Kinase experiment: | Leukocyte migration is measured using a modified 48-blind well microchemotaxis chamber equipped with 5 μm pore-sized nitrocellulose filters for CD14+ PBMC chemotaxis. In some experiments cells are incubated for 20 minutes with GFX (500 nM), Staurosporine (10 ng/mL), Tyrphostin-23 (10 ng/mL), Wortmannin (WTN) (10 nmol/liter), Protein kinase A inhibitor (PKI) (from 0.1 to 100 ng/mL) or Rp-cAMPS (from 100 pM to 100 μM), or CTX (1 nM) or pertussis toxin (PTX) (1 nM). For determination of Katacalcin 's potency to deactivate CD14+ PBMC chemotaxis toward fMLP, cells are incubated with Katacalcin (from 1 amol/liter to 1 μmol/liter) for 20 minutes. For control, cAMP-independent migration of CD14+ PBMC toward bombesin is tested in some of the experiments. After washing twice, 50 μL of a cell suspension (1×106 cells/mL) is put into the upper compartment of the chemotaxis chamber and cells are allowed to migrate for 90 minutes toward peptides derived from the calc-1 gene in the lower wells. After these migration periods, the filters are dehydrated, fixed, and stained with hematoxylin and eosin. Migration depth is quantified by microscopy, measuring the distance from the surface of the filter to the leading front of three cells migration[2]. |
References: [1]. Hillyard CJ, et al. Katacalcin: a new plasma calcium-lowering hormone. Lancet. 1983 Apr 16;1(8329):846-8. | |
| Cas No. | 85916-47-8 | SDF | |
| 别名 | 抗钙素; PDN 21 | ||
| Canonical SMILES | Asp-Met-Ser-Ser-Asp-Leu-Glu-Arg-Asp-His-Arg-Pro-His-Val-Ser-Met-Pro-Gln-Asn-Ala-Asn | ||
| 分子式 | C97H154N34O36S2 | 分子量 | 2436.6 |
| 溶解度 | Soluble in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.4104 mL | 2.052 mL | 4.1041 mL |
| 5 mM | 0.0821 mL | 0.4104 mL | 0.8208 mL |
| 10 mM | 0.041 mL | 0.2052 mL | 0.4104 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet